# Study of Biomarkers of Airway Inflammation (0000-128)

> **NCT00869596** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 22 (actual)

## Conditions studied

- Airway Inflammation

## Interventions

- **DRUG:** fluticasone propionate
- **DRUG:** Comparator: Placebo to fluticasone
- **DRUG:** Comparator: Lipopolysaccharide (LPS)
- **DRUG:** Comparator: albuterol

## Key facts

- **NCT ID:** NCT00869596
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2015-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00869596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00869596, "Study of Biomarkers of Airway Inflammation (0000-128)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00869596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*